Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
George D. Demetri(Dana-Farber Cancer Institute), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Andrew J. Wagner(Dana-Farber Cancer Institute), Jonathan C. Trent(University of Miami), John Zalcberg(Monash Health), Claudia Valverde(Vall d'Hebron Hospital Universitari), Nadia Hindi(Hospital Universitario Fundación Jiménez Díaz), Roberta Maestro(Centro di Riferimento Oncologico), Javier Martín‐Broto(Hospital Universitario Fundación Jiménez Díaz), Angelo Paolo Dei Tos(University of Padua), Hans Gelderblom(Leiden University Medical Center), E. Wardelmann(University of Münster), William D. Tap(Memorial Sloan Kettering Cancer Center), Bodil Bjerkehagen(Oslo University Hospital), Akira Kawai(NTT (Japan)), Rick L. Haas(Leiden University Medical Center), Matías Chacón(Instituto Alexander Fleming), Peter Hohenberger(University of Mannheim), Robin L. Jones(Institute of Cancer Research), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Kjetil Boye(Oslo University Hospital), Ian Judson(Erasmus Hospital), César Serrano(Vall d'Hebron Institut de Recerca), Winette T.A. van der Graaf(The Netherlands Cancer Institute), Chandrajit P. Raut(Dana-Farber Cancer Institute), David M. Thomas(New South Wales Department of Health), Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Frédérique Penault‐Llorca(Inserm), Yoichi Naito(National Cancer Center Hospital East), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Marta Sbaraglia(University of Padua), Lin Shen(Peking University), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Jayesh Desai(Peter MacCallum Cancer Centre), Suzanne George(Dana-Farber Cancer Institute), Judith V.M.G. Bovée(Leiden University Medical Center), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Inga‐Marie Schaefer(Brigham and Women's Hospital), Kirsten Sundby Hall(Oslo University Hospital), Akmal Safwat(Aarhus University Hospital), Heikki Joensuu(Orion Corporation (Finland)), Y-K Kang(Ulsan College), P. Schöffski(KU Leuven), Jonathan A. Fletcher(Harvard University), Axel Le Cesne(Institut Gustave Roussy), M. von Mehren(Fox Chase Cancer Center), Shreyaskumar Patel(The University of Texas MD Anderson Cancer Center)
Cited by 145
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k